By Jo Cavallo
The Circulating Cell-free Genome Atlas Study is a large multicenter, case-controlled, observational study of 15,254 participants, 56% with cancer and 44% without cancer, with longitudinal follow-up to support the development of a cell-free DNA (cfDNA) multicancer early … Read more
BOSTON–(BUSINESS WIRE)– Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced results from the ongoing investigator-initiated Phase 1 clinical study investigating VS-6766, its
By Matthew Stenger
In a first-in-human phase I trial reported in the Journal of Clinical Oncology, Desai et al found that the RAF family kinase inhibitor lifirafenib produced responses in several solid tumor types in patients with BRAF or … Read more
BOSTON – In patients with advanced ovarian cancer, a combination of drugs known as immune checkpoint inhibitors and PARP inhibitors can produce powerful remissions, clinical trials have shown, but up until now investigators haven’t been able to predict which patients … Read more
Researchers have developed a simple blood test that measures the body’s own immune response to improve diagnosis of ovarian cancer.
Ovarian cancer is one of the most common gynecologic cancers, with the highest mortality rate. About 300,000 new cases are … Read more
Scientists at Uppsala University and the Sahlgrenska Academy, University of Gothenburg say they have developed a blood test that may provide a more precise diagnostic for suspected ovarian cancer that would eliminate the need for exploratory surgery. This could lead … Read more
By Michael Brown
Oncologists may soon have an accurate and inexpensive way of differentiating between types of ovarian cancer that will improve how patients are treated, thanks to findings from a national research study co-led out of the University of … Read more
By
Researchers have discovered a curious difference between the DNA from cancer cells and that from healthy cells, and this finding could lead to a new blood test for cancer.
The difference? Cancer DNA has a … Read more
By Rich Haridy
Promising early results are in from a phase 1 clinical trial into the safety and efficacy of a new cancer vaccine. The new treatment is designed to stimulate the immune system into attacking certain cancers known to … Read more
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but never to a cure. About 15 percent of
… Read moreBy Diane Mapes
Despite its long-standing nickname, ovarian cancer isn’t really a silent killer. There are symptoms; it’s just that they whisper or are commonly mistaken for something else, like aging or irritable bowel syndrome. As a result of this
Colon, pancreatic, stomach, or ovarian cancer; it increasingly shouldn’t matter. In an era of precision medicine, the treatment approach should reflect the genetic makeup of the person’s tumor and the presence or absence of key biomarkers.
That ethos was set … Read more
By: Annette McElhiney
Many of you have already read Dr. Maurie Markman’s article “In Ovarian Cancer Advancements, Finding New Biomarkers is Key” posted in the Clearity blog. It provoked me as an ovarian cancer survivor and non-medical professional … Read more
The search for validated, actionable biomarkers may be more important than initiating more phase 3 trials in the field of ovarian cancer, according to Maurie Markman, M.D.
“In the ovarian cancer arena, we have 30 years of history of doing … Read more
